Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex
Open Access
- 6 March 2020
- journal article
- research article
- Published by Springer Nature in Genome Medicine
- Vol. 12 (1) , 1-8
Abstract
Background: A comprehensive understanding of the pre-existing genetic variation in genes associated with antibiotic resistance in the Mycobacterium tuberculosis complex (MTBC) is needed to accurately interpret whole-genome sequencing data for genotypic drug susceptibility testing (DST). Methods: We investigated mutations in 92 genes implicated in resistance to 21 anti-tuberculosis drugs using the genomes of 405 phylogenetically diverse MTBC strains. The role of phylogenetically informative mutations was assessed by routine phenotypic DST data for the first-line drugs isoniazid, rifampicin, ethambutol, and pyrazinamide from a separate collection of over 7000 clinical strains. Selected mutations/strains were further investigated by minimum inhibitory concentration (MIC) testing. Results: Out of 547 phylogenetically informative mutations identified, 138 were classified as not correlating with resistance to first-line drugs. MIC testing did not reveal a discernible impact of a Rv1979c deletion shared by M. africanum lineage 5 strains on resistance to clofazimine. Finally, we found molecular evidence that some MTBC subgroups may be hyper-susceptible to bedaquiline and clofazimine by different loss-of-function mutations affecting a drug efflux pump subunit (MmpL5). Conclusions: Our findings underline that the genetic diversity in MTBC has to be studied more systematically to inform the design of clinical trials and to define sound epidemiologic cut-off values (ECOFFs) for new and repurposed anti-tuberculosis drugs. In that regard, our comprehensive variant catalogue provides a solid basis for the interpretation of mutations in genotypic as well as in phenotypic DST assays.Keywords
Funding Information
- Wellcome Trust (214560/Z/18/Z)
- Oscar II Jubileé Foundation (NA)
- Health Innovation Challenge Fund (WT098600, HICF-T5-342)
- German Center for Infection Research (NA)
- Leibniz Science Campus “Evolutionary Medicine of the Lung” (NA)
- Joachim Herz Stiftung
This publication has 51 references indexed in Scilit:
- Importance of the Genetic Diversity within the Mycobacterium tuberculosis Complex for the Development of Novel Antibiotics and Diagnostic Tests of Drug ResistanceAntimicrobial Agents and Chemotherapy, 2012
- A Point Mutation in cycA Partially Contributes to the D-cycloserine Resistance Trait of Mycobacterium bovis BCG Vaccine StrainsPLOS ONE, 2012
- Impact of fgd1 and ddn Diversity in Mycobacterium tuberculosis Complex on In Vitro Susceptibility to PA-824Antimicrobial Agents and Chemotherapy, 2011
- Molecular Investigation of Resistance to the Antituberculous Drug Ethionamide in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2011
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing dataGenome Research, 2010
- FastTree 2 – Approximately Maximum-Likelihood Trees for Large AlignmentsPLOS ONE, 2010
- The Sequence Alignment/Map format and SAMtoolsBioinformatics, 2009
- Fast and accurate short read alignment with Burrows–Wheeler transformBioinformatics, 2009
- Evolution, Population Structure, and Phylogeography of Genetically Monomorphic Bacterial PathogensAnnual Review of Microbiology, 2008
- Novel Mutations in ndh in Isoniazid-Resistant Mycobacterium tuberculosis IsolatesAntimicrobial Agents and Chemotherapy, 2001